Last reviewed · How we verify
NCT07361926: SHARP
Sexual Health Access at Retail Pharmacies: Advancing Pharmacy-based Delivery of Primary STI and HIV Prevention for Cisgender Women
NA trial testing doxy-PEP in Sexually Transmitted Infections (Not HIV or Hepatitis) in 720 participants. Not yet recruiting.
1 June 2029
Quick facts
| Lead sponsor | University of Washington |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 720 |
| Start date | 1 May 2026 |
| Primary completion | 1 June 2029 |
| Estimated completion | 1 June 2030 |
Drugs / interventions tested
- doxy-PEP — full drug profile →
- Serial STI testing
- HIV PEP/PrEP — full drug profile →
Conditions studied
- Sexually Transmitted Infections (Not HIV or Hepatitis) — all drugs for Sexually Transmitted Infections (Not HIV or Hepatitis) →
- HIV Infections — all drugs for HIV Infections →
Sponsor
University of Washington
Who can join
Adults 15 to 24, female only, with Sexually Transmitted Infections (Not HIV or Hepatitis) or HIV Infections. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
HIV PrEP initiation
Time frame: From enrollment to the end of participant follow up after 12 months
HIV PrEP initiation among women seeking contraception at retail pharmacies defined as accepting either daily oral PrEP pills or the DPV-VR when offered at enrollment and evidence of self-reported use at 1-month post-acceptance -
HIV PrEP persistence
Time frame: From enrollment to the end of participant follow up at 12 months
PrEP persistence defined as continuing with HIV PrEP use at 12-months -
STI incidence
Time frame: From enrollment to the end of participant follow up at 12 months
STI incidence (CT, NG, and/or syphilis)
Sponsor's own description
This proposed 3-arm randomized study will compare different pharmacy based approaches that include HIV prevention medication (PrEP and PEP), routine STI testing, and preventive antibiotic (doxycycline) for STIs. The study will assess how well these services can be implemented, how acceptable they are to young women, and whether they are cost-effective.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07361926
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sexually Transmitted Infections (Not HIV or Hepatitis)
Currently open trials in the same condition.
- NCT06203951 — Improving Perinatal Outcomes Among Kenyan Pregnant Women With an Integrated STI Testing Model · NA · recruiting
- NCT06266416 — IMARA for Black Male Caregivers and Girls Empowerment (IMAGE) · NA · recruiting
Other University of Washington trials
Trials by the same sponsor.
- NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
- NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
- NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
- NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07361926 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Washington
- Last refreshed: 26 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07361926.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing